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Time to Kick the Habit*Hillel Sternlicht, MD, George L. Bakris, MDSEE PAGE 379E arly cardiovascular (CV) outcome trials ofpatients with hypertension used high-dosethiazide diuretic agents, often 100 mg of
hydrochlorothiazide or 50 to 100 mg of chlorthali-
done (1–4). Although these studies showed consis-
tently greater CV risk reduction versus placebo, the
MRFIT (Multiple Risk Factor Intervention Trial)
study, which used both hydrochlorothiazide (HCTZ)
and chlorthalidone, noted a greater reduction in CV
events in the chlorthalidone arm, such that all partic-
ipants were eventually transitioned to this agent.
Retrospective analysis subsequently conﬁrmed that
there were fewer CV events in those treated with
chlorthalidone (5). A recent analysis of smaller
studies demonstrated that chlorthalidone is more
potent than HCTZ, resulting in a larger antihyperten-
sive effect, but also in more hypokalemia (6).
Further differences between agents comes from
ambulatory blood pressure monitoring (ABPM) data
showing that chlorthalidone has preserved antihy-
pertensive effects beyond 24 h, whereas HCTZ has
antihypertensive effects for approximately 12 to 14 h
(7,8). This is particularly important, as the highest
rates of CV events are in the early morning hours, a
time when blood pressure levels are at their highest
and shorter-acting agents from the day prior are no
longer effective (9).*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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disclose.Despite the overwhelming CV outcome data and
established 24-h efﬁcacy of chlorthalidone, prescrip-
tion patterns are unchanged, with HCTZ remaining
the drug of choice due to concerns regarding hypo-
kalemia and greater likelihood of new-onset diabetes.
This is despite long-term (>12-year) follow-up of
the ALLHAT (Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial) cohort
showing that new-onset diabetes and hypokalemia
did not adversely affect outcomes of interest when
treated appropriately (10).In this issue of the Journal, Pareek et al. (11)
report the results of a randomized double-blind trial
evaluating the efﬁcacy of low-dose chlorthalidone
(6.25 mg), HCTZ (12.5 mg), or a continuous-release
HCTZ, known as HCTZ-CR (12.5 mg), over a 12-week
period. The primary outcome was a change in 24-h
ambulatory systolic and diastolic blood pressure
between time zero and weeks 4 and 12. Patients were
required to be younger than 65 years of age, have
stage 1 hypertension (systolic pressure <160 mg Hg,
diastolic pressure <100 mm Hg), and be free of
additional comorbidities. Fifty-four patients were
enrolled, with a mean ofﬁce blood pressure of
149/93 mm Hg. At both 4 and 12 weeks, patients
receiving chlorthalidone or HCTZ-CR experienced
signiﬁcant declines in blood pressure by ABPM,
whereas those given the standard preparation HCTZ
did not. At 12 weeks, patients treated with chlorthali-
done or HCTZ-CR achieved blood pressure reductions
of 11.1/7.8 mm Hg, and 10.3/8.2 mm Hg, respectively,
versus 6.0/4.2 mm Hg in the HCTZ arm. Perhaps more
notable were the differences in nocturnal pressures
noted by ABPM between HCTZ and the other groups.
The chlorthalidone and HCTZ-CR groups had mean
nocturnal systolic pressure decreases of 10.2 and
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39112.7 mm Hg, respectively; those receiving HCTZ had
decreases in systolic blood pressure of 4.9 mm Hg. It is
therefore the overnight and early morning blood
pressure readings that illustrate the major advantage
between these agents. Finally, although the criteria for
adverse electrolyte or metabolic effects were not spe-
ciﬁcally deﬁned, no episodes of hyponatremia were
noted, and rates of hypokalemia and hyperuricemia
were similar among treatment groups.
It could be argued that the superiority of chlor-
thalidone in CV outcome trials is not attributable to
its potency but rather its duration of action given
its extended effects on nocturnal blood pressure. As
such, HCTZ-CR was able to achieve comparable
antihypertensive effects in terms of blood pressure
reduction and duration of effect. These long-acting
preparations are crucial to blood pressure control
during the early morning hours, when one is
most vulnerable to CV events. That such low doses
can achieve meaningful reductions in blood pres-
sure is not surprising. A recent meta-analysis (12)
notes that low-dose administration typically cap-
tures approximately 75% of the antihypertensive
efﬁcacy of full-dose therapy, while provoking only
25% of the adverse events. Although this trial may
appear to reﬂect a lower rate of side effects, spe-
ciﬁcally the absence of hyponatremia, the trial
duration was short, the study was underpowered
to detect this outcome, and those at highest risk,that is, people older than 65 years of age, were
excluded.
The larger question is, are these data generalizable
to a broader population? Although the pharmacology
and blood pressure-lowering effects are indisputable,
the study design has limitations. First, only one-third
of those screened were enrolled, suggesting that just
a fraction of the patients seen on a daily basis would
ﬁt the focused study criteria, namely the exclusion of
those with any additional comorbidities or an age in
excess of 65 years. Additionally, because the study
was conducted in a Southeast Asian country, it re-
mains unclear whether the results can be extrapo-
lated to those on Western diets or of other ethnicities.
Finally, given the small number of patients per arm,
the standard deviation around a given reduction in
pressure was extremely wide, suggesting that the
true effect in a broader population may be markedly
different.
In conclusion, the clear message is that a low dose
of a long-acting diuretic therapy can have a mean-
ingful impact on the management of hypertension
and on CV outcomes.
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